Finance

Lists
Q2 2026 earnings • released • EPS beat +51.73% • Revenue beat +1.92%
See results
VTR:NYSE
Ventas Inc
$93.51
0.00%
(0.00) 1D
Jul 31, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VTR...
Mkt. cap
45.46B
Avg. vol.
4.04M
Volume
860.00
Dividend
2.14%
Quarterly dividend
$0.50
Ex-dividend date
Jun 30, 2026
P/E ratio
171.56
52-wk high
$101.60
52-wk low
$66.38
EPS
$0.55
Beta
0.69
Shares outstanding
512.95M
No. of employees
542
Mkt. cap
45.46B
Avg. vol.
4.04M
Volume
860.00
Dividend
2.14%
Quarterly dividend
$0.50
Ex-dividend date
Jun 30, 2026
P/E ratio
171.56
52-wk high
$101.60
52-wk low
$66.38
EPS
$0.55
Beta
0.69
Shares outstanding
512.95M
No. of employees
542
News stories
From sources across the web
Profile
Ventas, Inc. is a real estate investment trust specializing in the ownership and management of research, medicine and healthcare facilities in the United States, Canada and the United Kingdom. As of December 2019, the group's portfolio consisted of 1,200 properties divided among nursing homes, medical office buildings, rehabilitation and acute care centres, special care centres, laboratories and research centres and medical-surgical centres for a total value of nearly $25 billion. As of 2019, it is a Fortune 1000 corporation. Wikipedia
About Ventas Inc
CEODebra Cafaro
Employees542
Founded1998
HeadquartersChicago, Illinois, United States
SectorReal estate investment trust
Websiteventasreit.com
Analyst ratings
Based on 17 analysts giving stock ratings to VTR in the past 3 months
Strong buy
Buy
13
Hold
4
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for VTR in the last 3 months.
Highest
Current $93.51
$114.00 (+21.91%)
Average
$99.82 (+6.75%)
Lowest
$90.00 (-3.75%)
Analyst
Recommendation
Action
Price target
Projected
Date
Nicholas Joseph
Citi
Buy
Maintained
$100.00
+6.9%
08/03/2026
Jeffrey Spector
Bank of America Securities
Buy
Reiterated
$113.00
+20.8%
08/03/2026
Richard Anderson
Cantor Fitzgerald
Buy
Reiterated
$102.00
+9.1%
07/31/2026
James Kammert
Evercore ISI
Buy
Maintained
$96.00
+2.7%
07/30/2026
Nicholas Yulico
Scotiabank
Hold
Maintained
$93.00
-0.5%
07/30/2026
Vikram Malhotra
Mizuho Securities
Buy
Maintained
$104.00
+11.2%
07/22/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
$114.00
+21.9%
07/15/2026
Juan C. Sanabria
BMO Capital
Buy
Reiterated
$100.00
+6.9%
07/13/2026
Richard Hightower
Barclays
Hold
Initiated
$99.00
+5.9%
07/07/2026
Unknown Analyst
Raymond James
Buy
Initiated
$94.00
+0.5%
06/16/2026
Dave Rodgers
Raymond James
Buy
Initiated
$94.00
+0.5%
06/16/2026
Omotayo Okusanya
Deutsche Bank
Buy
Maintained
$100.00
+6.9%
06/16/2026
Julien Blouin
Goldman Sachs
Buy
Maintained
$110.00
+17.6%
06/03/2026
Ronald Kamdem
Morgan Stanley
Hold
Reiterated
$90.00
-3.8%
06/02/2026
Jonathan Petersen
Jefferies
Buy
Maintained
$100.00
+6.9%
05/12/2026
Michael Mueller
J.P. Morgan
Buy
Reiterated
$94.00
+0.5%
05/11/2026
Austin Wurschmidt
KeyBanc
Buy
Maintained
$95.00
+1.6%
05/07/2026
Michael Goldsmith
UBS
Hold
Maintained
$93.00
-0.5%
05/04/2026
Michael Carroll
RBC Capital
Buy
Maintained
$98.00
+4.8%
05/01/2026
John Kilichowski
Wells Fargo
Buy
Maintained
$93.00
-0.5%
03/26/2026
Marie Ferguson
Argus Research
Buy
Maintained
$88.00
-5.9%
02/09/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.17 / $0.11
+51.73%beat
Revenue / Est. (USD)
1.72B / 1.69B
+1.92%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.50B
1.55B
1.65B
1.72B
Cost of goods sold
869.92M
937.40M
1.00B
1.04B
Cost of revenue
869.92M
937.40M
1.00B
1.04B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40.39M
41.01M
62.75M
46.99M
Operating expense
397.56M
297.53M
416.91M
454.70M
Total operating expenses
1.27B
1.23B
1.42B
1.50B
Operating income
233.98M
315.49M
226.81M
222.70M
Other non operating income
-13.37M
-4.20M
-9.70M
-4.45M
EBT including unusual items
62.36M
71.87M
43.11M
46.60M
EBT excluding unusual items
66.67M
164.69M
63.47M
59.99M
Income tax expense
-6.34M
-1.12M
-15.94M
-25.62M
Effective tax rate
-10.17%
-1.56%
-36.97%
-54.97%
Other operating expenses
-
-
-
-
Net income
66.05M
70.20M
55.91M
70.57M
Net profit margin
4.40%
4.53%
3.39%
4.10%
Earnings per share
0.12
0.13
0.10
0.17
Interest and investment income
4.18M
7.88M
2.50M
1.78M
Interest expense
-158.12M
-154.47M
-156.14M
-160.03M
Net interest expenses
-153.94M
-146.59M
-153.64M
-158.26M
Depreciation and amortization charges
357.17M
256.52M
354.17M
407.71M
EBITDA
559.73M
659.02M
585.75M
581.64M
Gain or loss from assets sale
-1.28M
-3.31M
-15.06M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps